CoChat

Comparative effectiveness of dulaglutide versus liraglutide in Asian type 2 diabetes patients: a multi-institutional cohort study and meta-analysis

Open access

Published version of a preprint

The DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index.

Abstract

Background: Head-to-head comparison of clinical effectiveness between dulaglutide and liraglutide in Asia is limited. This study was aimed to assess the real-world comparative effectiveness of dulaglutide versus liraglutide. Methods: We conducted a retrospective cohort study by utilizing multi-institutional electronic medical records to identify real-world type 2 diabetes patients treated with dulaglutide or liraglutide during 2016–2018 in Taiwan and followed up until 2019. Effectiveness outcomes were assessed at every 3 months in the 1-year follow-up. Propensity score techniques were applied to enhance between-group comparability. Significant differences in changes of effectiveness outcomes between treatment groups during the follow-up were examined and further analyzed using mixed-model repeated-measures approaches. Results: A total of 1512 subjects receiving dulaglutide and 1513 subjects receiving liraglutide were identified. At 12 months, significant HbA1c changes from baseline were found in both treatments (dulaglutide: − 1.06%, p < 0.001; liraglutide: − 0.83%, p < 0.001), with a significant between-group difference (− 0.23%, 95% confidence interval − 0.38 to − 0.08%, p < 0.01). Both treatments yielded significant declines in weight, alanine aminotransferase level, and estimated glomerular filtration rate from baseline (dulaglutide: − 1.14 kg, − 3.08 U/L and − 2.08 mL/min/1.73 m 2 , p < 0.01; liraglutide: − 1.64 kg, − 3.65 U/L and − 2.33 mL/min/1.73 m 2 , p < 0.001), whereas only dulaglutide yielded a significant systolic blood pressure reduction (− 2.47 mmHg, p < 0.001). Between-group differences in changes of weight, blood pressure, and liver and renal functions at 12 months were not statistically significant. Conclusions: In real-world T2D patients, dulaglutide versus liraglutide was associated with better glycemic control and comparable effects on changes of weight, blood pressure, and liver and renal functions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12933-020-01148-8

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Flow chart of cohort selection and outline of analytic procedures. IPTW inverse probability of treatment weighting, SMRW standardized mortality ratio weighting
Fig. 1 Flow chart of cohort selection and outline of analytic procedures. IPTW inverse probability of treatment weighting, SMRW standardized mortality ratio weightingCC BY · PubMed Central
Fig. 2 Changes in clinical effectiveness at every 3 months after initiation of dulaglutide or liraglutide (based on the propensity-score-matched sample). a HbA1c values from baseline to month 12, b change in HbA1c from baseline to month 12, c body weights from baseline to month 12, d change in body weight from baseline to month 12, e systolic blood pressure (SBP) from baseline to month 12, f change in SBP from baseline to month 12, g alanine aminotransferase (ALT) values from baseline to month 12, h change in ALT from baseline, i estimated glomerular filtration rates (eGFR) from baseline to month 12, and j change in eGFR from baseline to month 12. Index date refers to the first date of initiation of dulaglutide or liraglutide. *, **, and *** refer to p value < 0.05, < 0.01, and < 0.001, respectively
Fig. 2 Changes in clinical effectiveness at every 3 months after initiation of dulaglutide or liraglutide (based on the propensity-score-matched sample). a HbA1c values from baseline to month 12, b change in HbA1c from baseline to month 12, c body weights from baseline to month 12, d change in body weight from baseline to month 12, e systolic blood pressure (SBP) from baseline to month 12, f change in SBP from baseline to month 12, g alanine aminotransferase (ALT) values from baseline to month 12, h change in ALT from baseline, i estimated glomerular filtration rates (eGFR) from baseline to month 12, and j change in eGFR from baseline to month 12. Index date refers to the first date of initiation of dulaglutide or liraglutide. *, **, and *** refer to p value < 0.05, < 0.01, and < 0.001, respectivelyCC BY · PubMed Central
Fig. 3 Forest plot of 12-month difference in HbA1c between dulaglutide and liraglutide. a All studies (including randomized controlled trials [RCTs] and observational studies), b RCTs only, and c observational studies only
Fig. 3 Forest plot of 12-month difference in HbA1c between dulaglutide and liraglutide. a All studies (including randomized controlled trials [RCTs] and observational studies), b RCTs only, and c observational studies onlyCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 47 references

Cited by

See all 28

Metadata

Authors
Chang, K.-C., Shao, S.-C., Kuo, S., Yang, C.-Y., Chen, H.-Y., Chan, Y.-Y., & Ou, H.-T.
Affiliations
  • Linkou Chang Gung Memorial Hospital (TW)
  • Keelung Chang Gung Memorial Hospital (TW)
  • University of Michigan (US)
  • National Cheng Kung University (TW)
  • Chang Gung Memorial Hospital (TW)
  • National Cheng Kung University Hospital (TW)
Corresponding author
Ou, Huang-Tz
Venue
Cardiovascular Diabetology
Published
2020-10-09
Volume
19
Issue
1
Pages
172-172
ISSN
1475-2840 (ISSN-L)
OpenAlex
W3092048046
Cited by
28
References
48
Citations by year
2026: 2 · 2025: 5 · 2024: 10 · 2023: 5 · 2022: 4 · 2021: 2
FWCI
2.07
Type
journal article
Language
en
Open access
Licence
Locations
  • Cardiovascular Diabetology (publishedVersion, cc-by)
  • Research Square (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Deep Blue (University of Michigan) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Chang Gung Medical Foundation (CMRPG3K0101)
  • Ministry of Science and Technology, Taiwan (MOST 108-2320-B-006-048)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
dulaglutide, liraglutide, type 2 diabetes, comparative effectiveness, GLP-1 receptor agonists, glycemic control, HbA1c, weight loss, alanine aminotransferase, estimated glomerular filtration rate, systolic blood pressure, real-world evidence, Asian patients, Taiwan, propensity score matching
MeSH terms
Liraglutide, Glycemic Control, Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Immunoglobulin Fc Fragments, Male, Middle Aged, Recombinant Fusion Proteins, Retrospective Studies, Taiwan, Time Factors, Biomarkers, Treatment Outcome, Asian People, Comparative Effectiveness Research

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comparative effectiveness of dulaglutide versus liraglutide in Asian type 2 diabetes patients: a multi-institutional cohort study and meta-analysis. https://app.cochat.ai/papers/10.1186/s12933-020-01148-8
The paper
Chang, K.-C., Shao, S.-C., Kuo, S., Yang, C.-Y., Chen, H.-Y., Chan, Y.-Y., & Ou, H.-T. (2020). Comparative effectiveness of dulaglutide versus liraglutide in Asian type 2 diabetes patients: a multi-institutional cohort study and meta-analysis. Cardiovascular Diabetology. https://doi.org/10.1186/s12933-020-01148-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.